Skip to content

Effect of Pre-dosing With Methylcellulose or Psyllium on Colonic Fermentation of Inulin

Effect of Pre-dosing With Methylcellulose or Psyllium on Colonic Fermentation of Inulin (COCOA3)

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06494137
Acronym
COCOA3
Enrollment
35
Registered
2024-07-10
Start date
2024-10-31
Completion date
2025-03-31
Last updated
2024-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable Bowel Syndrome

Keywords

inulin, fermentation, colon

Brief summary

The aim for this pilot study is to test the hypothesis that pre-dosing with gel-forming dietary fibres (methylcellulose or psyllium) will alter the colonic fermentation of a model fermentable dietary fibre (Inulin) when delivered separately, in contrast to our previous trials where gel-forming and fermentable dietary fibres were co-administered. Performance of each gel-forming dietary fibre will be compared to placebo (water) to assess treatment effectiveness.

Detailed description

4\. BACKGROUND AND RATIONALE The challenge is to understand how various dietary fibres interact to alter colonic fermentation of FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides and polyols) with the aim of reducing gaseous distension of the colon and hence symptoms. Previous studies 1 have shown how psyllium, a gel forming natural fibre can reduce gas production induced by a dietary FODMAP inulin when it reaches the colon. The investigation will exploiting a range of food grade modified celluloses which can form gels at body temperature to perform human studies to explore whether the beneficial effect of psyllium is unique or will be found with all gelling substances 2. The mode of action of methylcellulose and psyllium on the reduction in gas production from inulin remains unclear. Possible mechanisms include 1) slowing delivery to the colon by their effect in the small bowel, 2) delayed release of inulin from the dietary fibre gel matrix (i.e. a physical effect) in the colon 3) or a direct effect on the colonic bacteria reducing their production of gas (i.e. a microbiological effect). References Aim This pilot study will test the hypothesis that pre-dosing with gel-forming dietary fibres (methylcellulose or psyllium) will alter the colonic fermentation of a model fermentable dietary fibre (Inulin) when delivered separately, in contrast to our previous trials where gel-forming and fermentable dietary fibres were co-administered. Performance of each gel-forming dietary fibre will be compared to placebo (water) to assess treatment effectiveness. Objective The primary objective of this pilot is to compare the effect of pre-feeding a gel-forming dietary fibre (methylcellulose or psyllium) compared to placebo (water) on the colonic fermentability of Inulin over the six hours immediately post inulin ingestion as assessed from breath hydrogen production. Secondary Objectives 1. Area under curve (AUC) of breath hydrogen and methane for period 0 - 24hr. 2. Orocecal transit time (OCTT) from breath analysis. 3. Whole gut transit time assessed by blue muffin test. 4. Gas production with in vitro model of colon using participants stool samples (Quadram Institute). 5. Metabolite production (short chain fatty acids) using same in vitro model of colon (Quadram Institute). 6. Analysis of microbiota in participants stool using 16sRNA gene (in collaboration with Quadram Institute). 7. Assessment of habitual dietary FODMAP intake on breath hydrogen response to Inulin

Interventions

OTHERinulin

inulin from chicory root

Sponsors

Quadram Institute Bioscience
CollaboratorOTHER
University of Nottingham
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Masking description

gels given in opaque plastic bag

Intervention model description

randomised placebo controlled crossover study

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Aged between 18 and 65 years old. * Able to give informed consent. * Scoring ≤5 (i.e., mild, or less) for symptoms of flatulence, bloating, abdominal pain, loose stool, and hard stool in previous 2 weeks using a modified Gastrointestinal Symptom Rating Scale (5). * Agrees to consume the meals provided. * Agrees to not smoke during the breath hydrogen sampling period.

Exclusion criteria

* • Pregnancy, lactating, or planning pregnancy during the course of the investigation declared by candidate. * History declared by the candidate of pre-existing gastrointestinal disorder that may affect bowel function. * Reported history of previous resection of the oesophagus, stomach, or intestine (excluding appendix). * Intestinal stoma. * Any medical condition making participation potentially compromising participation in the study e.g., diabetes mellitus, respiratory disease limiting ability to use breath hydrogen analyser, known intolerance to one of the test substances. * Has a body mass index (BMI) value less than 18.5 or greater than 35. * Will not agree to follow dietary and lifestyle restrictions required. * Unable to stop drugs known to alter GI motility including mebeverine, opiates, monoamine oxidase inhibitors, phenothiazines, benzodiazepines, calcium channel antagonists for the duration of the study (Selective serotonin reuptake inhibitors, low dose tricyclic antidepressants, antihistamines, and oral contraceptive pill will be recorded in the CRF but will not be an

Design outcomes

Primary

MeasureTime frameDescription
Breath hydrogen AUC0-6 hoursArea under curve (AUC) from time 0-6 hours (AUC 0-6) of breath hydrogen (ppm.hour) after consumption of inulin intake.

Secondary

MeasureTime frameDescription
Breath hydrogen AUC0-24hArea under curve (AUC) from time 0-24hours (AUC 0-24) of breath hydrogen (ppm.hour) after consumption of inulin intake.
Whole gut transit0-7daysTime for blue colour to appear after ingesting muffin labelled with blue food colouring

Countries

United Kingdom

Contacts

Primary ContactRobin Spiller, MD
robin.spiller@nottingham.ac.uk07824328319
Backup ContactJoshuah Reid, PhD
sbzjer@exmail.nottingham.ac.uk07540418235

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026